Sunshine Biopharma (NASDAQ: “SBFM”) Reports 2023 First Quarter Results: Revenues Up 2,100%

MONTREAL, May 11, 2023 (GLOBE NEWSWIRE) — Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 2023 first quarter report. The Report shows gross revenues of $4,894,053 as of March 31, 2023, an increase […]

Mawson Infrastructure Group Inc. (NASDAQ:MIGI) Corrects Date for First Quarter Results Webcast for 5:00 p.m. ET on May 15, 2023

SHARON, Pa., May 10, 2023–(BUSINESS WIRE)–Mawson Infrastructure Group Inc. (NASDAQ:MIGI) (“Mawson” or the “Company”), a digital infrastructure provider, today announced that the company has scheduled a webcast for May 15, 2023 at 5:00 p.m. Eastern Time, to discuss results for the first quarter of 2023. A new Investor Presentation will be available on the website […]

OKYO Pharma (NASDAQ: OKYO) Now Participating on the Webull Corporate Communications Service Platform

Webull’s community of active participants can now access OKYO’s profile on the leading mobile-first brokerage platform LONDON and NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) — OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in this multi-billion-dollar […]

Laser Photonics (NASDAQ:LASE) Adds Three New Sales Hires To Focus on the Defense, Automotive and Energy Industries

ORLANDO, FL / ACCESSWIRE / May 10, 2023 / Laser Photonics Corporation (NASDAQ:LASE) (“LPC”), a leading global developer of industrial CleanTech laser systems for laser cleaning and other material applications, today announced it has hired three sales executives as part of its investment plan announced on April 17, 2023. “Hiring key account managers in our core verticals […]

WiSA Technologies, Inc.  (NASDAQ: WISA) to Host First Quarter 2023 Results Conference Call at 5:30 am Pacific Time | 8:30 am Eastern Time on May 16th

BEAVERTON, Ore., May 10, 2023–(BUSINESS WIRE)–WiSA Technologies, Inc. (NASDAQ: WISA), a developer of spatial, wireless sound technology for smart devices and next-generation home entertainment systems, will host its first quarter 2023 results conference call at 5:30 am PT / 8:30 am ET, on Tuesday, May 16, 2023. The conference call will be available through a live […]

Aegis Capital Initiates Coverage of Sharps Technology (Nasdaq: STSS) with $16 Buy Recommendation

Fintel reports that on May 9, 2023, Aegis Capital initiated coverage of Sharps Technology (NASDAQ:STSS) with a Buy recommendation. What is the Fund Sentiment? There are 9 funds or institutions reporting positions in Sharps Technology. This is an increase of 8 owner(s) or 800.00% in the last quarter. Total shares owned by institutions increased in the last three months by 0.35% […]

Mawson Infrastructure Group Inc. (NASDAQ:MIGI) Schedules First Quarter Results Webcast for 5:00 p.m. ET on May 11, 2023

SHARON, Pa., May 09, 2023–(BUSINESS WIRE)–Mawson Infrastructure Group Inc. (NASDAQ:MIGI) (“Mawson” or the “Company”), a digital infrastructure provider, today announced that the company has scheduled a webcast for May 11, 2023 at 5:00 p.m. Eastern Time, to discuss results for the first quarter of 2023. A new Investor Presentation will be available on the website […]

Amesite Inc. (NASDAQ: AMST) to Present at Sidoti Virtual Investor Conference May 10, 2023

DETROIT, May 09, 2023 (GLOBE NEWSWIRE) — Amesite Inc. (NASDAQ: AMST), a leading artificial intelligence software company offering a cloud-based learning platform for business and education markets, announced today its Founder and CEO, Dr. Ann Marie Sastry will present and host one-on-one meetings with investors at the Sidoti May Micro-Cap Virtual Conference, taking place on […]

Longeveron (NASDAQ: LGVN) Announces New Long-Term Survival Data from ELPIS I Trial of Lomecel-B™ for Hypoplastic Left Heart Syndrome

– Children in the ELPIS I trial had 100% survival up to 5 years of age after receiving Lomecel-BTM compared to 20% mortality rate observed from historical control data – – Data reinforce potential survival benefit of Lomecel-BTM for patients with hypoplastic left heart syndrome (HLHS) – – Enrollment ongoing in Phase 2a ELPIS II trial – – […]

Start Expanding
Your Shareholder Base

Let us help you connect with investors
committed to your success.